NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the retirement of Werner Cautreels, PhD, from his role as Chief Executive Officer, effective March 31, 2025. This leadership transition will coincide with the company’s Annual Report filing. Dr. Cautreels will remain a member of the Board of Directors and serve as a special advisor to the Board for the coming year.
Taking the helm as Interim CEO is Iain D. Dukes, D Phil, who will also continue in his current capacity as Chairman of the Board. Dr. Dukes brings extensive leadership experience from both public and private biopharmaceutical companies, with expertise spanning corporate strategy and product development.
“On behalf of the Board of Directors, I want to express my sincerest appreciation to Werner for his unwavering commitment and dedicated service. Under his leadership, the Company completed the merger with Trawsfynydd to form Traws Pharma, advancing two exciting clinical-stage antiviral candidates for bird flu and COVID,” said Dr. Dukes. “I believe that Traws’ novel antiviral programs have the potential to substantially improve the care of people with influenza and COVID. We look forward to reviewing the Company’s pipeline progress in our Investor Update call on March 31, 2025.”
Dr. Cautreels, who played a pivotal role in navigating Traws Pharma through its merger and subsequent development milestones, expressed his gratitude for the opportunity. “I am grateful to the employees, advisors, investors and collaborators who have supported Traws’ development and progress since the merger, just one year ago. It has been a privilege to work with such an impressive management team, and advance our bird flu and COVID programs, while garnering the support of important institutional investors,” he stated. “I look forward to continuing to support Traws in my new role, as the Company takes the next steps in the development of its portfolio of oral small molecule antivirals.”
Under Dr. Cautreels’ leadership, Traws Pharma has achieved significant milestones, including advancing its clinical-stage antiviral candidates targeting both bird flu and COVID. The company remains focused on developing innovative treatments with the potential to transform patient outcomes in the fight against global infectious diseases.
This leadership shift marks an exciting new chapter for Traws Pharma as it builds on its progress and prepares to share updates about its pipeline later this month.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.